Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response

[1]  Geoffrey Kemball-Cook,et al.  Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver. , 2006, Blood.

[2]  J. Rasko,et al.  ERRATUM: People to watch , 2006, Nature Medicine.

[3]  J. F. Wright,et al.  Identification of factors that contribute to recombinant AAV2 particle aggregation and methods to prevent its occurrence during vector purification and formulation. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[4]  H. Stedman,et al.  Regional intravascular delivery of AAV-2-F.IX to skeletal muscle achieves long-term correction of hemophilia B in a large animal model. , 2005, Blood.

[5]  Lili Wang,et al.  Sustained correction of disease in naive and AAV2-pretreated hemophilia B dogs: AAV2/8-mediated, liver-directed gene therapy. , 2005, Blood.

[6]  W. Xiao,et al.  Intracellular Viral Processing, Not Single-Stranded DNA Accumulation, Is Crucial for Recombinant Adeno-Associated Virus Transduction , 2004, Journal of Virology.

[7]  L. Couto,et al.  Direct exposure of mouse spermatozoa to very high concentrations of a serotype-2 adeno-associated virus gene therapy vector fails to lead to germ cell transduction. , 2004, Human gene therapy.

[8]  Victor Appay,et al.  Lessons from the study of T-cell differentiation in persistent human virus infection. , 2004, Seminars in immunology.

[9]  Theresa A. Storm,et al.  Rapid Uncoating of Vector Genomes Is the Key toEfficient Liver Transduction with Pseudotyped Adeno-Associated VirusVectors , 2004, Journal of Virology.

[10]  A. Parker,et al.  Sustained phenotypic correction of canine hemophilia A using an adeno-associated viral vector. , 2003, Blood.

[11]  B. Boehm,et al.  CD4+ and CD8+ cells in cryopreserved human PBMC maintain full functionality in cytokine ELISPOT assays. , 2003, Journal of immunological methods.

[12]  Alan McClelland,et al.  AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. , 2003, Blood.

[13]  Alan McClelland,et al.  Quantification of adeno-associated virus particles and empty capsids by optical density measurement. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[14]  C. Slaughter,et al.  Sustained high-level expression of human factor IX (hFIX) after liver-targeted delivery of recombinant adeno-associated virus encoding the hFIX gene in rhesus macaques. , 2002, Blood.

[15]  R. Herzog,et al.  Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy. , 2002, Blood.

[16]  Sylvia Janetzki,et al.  A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. , 2002, Journal of immunological methods.

[17]  J. Biegel,et al.  Lack of germline transmission of vector sequences following systemic administration of recombinant AAV-2 vector in males. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[18]  Jean Bennett,et al.  Gene therapy restores vision in a canine model of childhood blindness , 2001, Nature Genetics.

[19]  M. Kay,et al.  Inclusion of the hepatic locus control region, an intron, and untranslated region increases and stabilizes hepatic factor IX gene expression in vivo but not in vitro. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[20]  Alan McClelland,et al.  Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector , 2000, Nature Genetics.

[21]  I. Verma,et al.  Sustained expression of therapeutic level of factor IX in hemophilia B dogs by AAV-mediated gene therapy in liver. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[22]  R. Samulski,et al.  Persistent expression of canine factor IX in hemophilia B canines , 1999, Gene Therapy.

[23]  Katherine A. High,et al.  Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector , 1999, Nature Medicine.

[24]  M. Kay,et al.  Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors , 1999, Nature Medicine.

[25]  R. Ljung.  Can haemophilic arthropathy be prevented? , 1998, British journal of haematology.

[26]  H. Pettersson,et al.  Haemophilia prophylaxis in young patients–a long‐term follow‐up , 1997, Journal of internal medicine.

[27]  S. Cai,et al.  Therapeutic levels of functional human factor X in rats after retroviral-mediated hepatic gene therapy. , 1997, Blood.

[28]  P. Bedossa,et al.  An algorithm for the grading of activity in chronic hepatitis C , 1996, Hepatology.

[29]  K. Kurachi,et al.  Role of Intron I in Expression of the Human Factor IX Gene (*) , 1995, The Journal of Biological Chemistry.

[30]  P. Bedossa,et al.  Intraobserver and Interobserver Variations in Liver Biopsy Interpretation in Patients with Chronic Hepatitis C , 1994 .